Elevated serum level and gene polymorphisms of TGF‐β1 in gastric cancer

Abstract

Transforming growth factor (TGF)-beta1, as a candidate tumor marker, is currently of interest. In this study, serum TGF-beta1 levels in gastric cancer (GC) patients and healthy volunteers were measured using enzyme-linked immunosorbent assay (ELISA). In addition, single nucleotide polymorphisms (SNPs) of the TGF-beta1 gene at codon 10 and codon 25 were identified by means of amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and sequence analysis. Our results indicated that serum concentrations of TGF-beta1 in GC patients were significantly higher than those in the control, and positively correlated with tumor mass, invasion, metastasis, and clinical stage. The serum TGF-beta1 levels of patients recovering from radical resection were markedly lower than those before surgery. Meanwhile, no deoxyribonucleic acid (DNA) sequence variation at codon 25 of the TGF-beta1 gene was found and a TGF-beta1 gene polymorphism at codon 10 did not show obvious correlations with either TGF-beta1 expression or clinicopathological parameters of GC. Our evidence suggested that serum concentration of TGF-beta1 might be a novel tumor marker for GC and the polymorphisms of TGF-beta1 gene did not play a role as a determinant of serum TGF-beta1 concentration or as a genetic risk factor in the gastric carcinogenesis and progression.

MicroRNAs in hereditary diffuse gastric cancer

“…In addition, it has been found that these are predisposed to develop GC (13) and that changes in the INSR gene (14) exert an effect on the insulin signaling pathway, giving rise to changes in the pattern of glycosylation of the E-cadherin protein, destabilization of cellular membranes and the appearance of a mesenchymal phenotype. Contrary to previously described, the roles of the mutations in the genes FBXO24, DOT1L (14) and TGF-β (15) have not yet been studied (Table I). Some of the mutations identified pertain to genes encoding regulatory elements or proteins that form complexes with protein E-cadherin; as a consequence of these, the loss of cellular adhesion can present due to deregulation of the complex.…”

Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers

“…36 In a similar manner, it was demonstrated that serum concentrations of TGF-β1 in gastric cancer patients were significantly higher than controls. 37 Han et al 23 were revealed that patients with cholangiocarcinomas, HCCs and gastric carcinomas presented increased serum TGF-β1 levels than non-cancer counterparts. It has been shown that the blockage of TGF-β causes upregulation of E-cadherin resulting in the reduction of migration and invasion of carcinoma cells 38 and then TGF-β1 expression negatively correlated with E-cadherin expression.…”

Gene polymorphism of transforming growth factor-β1 in Egyptian patients with type 2 diabetes and diabetic nephropathy

“…The human TGF-b1 gene is located on chromosome 19q13.1-13.3 [10], and more than 10 polymorphic loci are presently known, distributed in exons, introns, and the 5 0 -flanking region [11]. The hotspots focus on the single nucleotide polymorphisms (SNPs) of codons 10 and 25 [12]. The polymorphisms at codons 10 and 25 may be associated with higher or lower TGF-b1 synthesis in vitro [13].…”